Int J Stomatol

Int J Stomatol ›› 2023, Vol. 50 ›› Issue (2): 230-236.doi: 10.7518/gjkq.2023003

• Reviews • Previous Articles     Next Articles

Role of discoidin domain receptor 1 in the regulation of malignant tumor progression and therapy

Li Tan(),Liang Xin-hua.()   

  1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Oral Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2022-07-19 Revised:2022-11-10 Online:2023-03-01 Published:2023-03-14
  • Contact: Xin-hua. Liang E-mail:18843113788@163.com;lxh88866@scu.edu.cn
  • Supported by:
    National Natural Science Foundation of China(82073000)

RichHTML

22

PDF (PC)

246

Abstract:

Discoidin domain receptor 1 (DDR1) is a special type of transmembrane receptor tyrosine kinase that is aberrantly expressed in various tumors, including oral squamous cell carcinoma, and can regulate molecular pathways related to tumor progression. DDR1 is involved in a variety of biological processes, such as cell proliferation, differentiation, migration, invasion, dormancy, and apoptosis, and is also closely related to tumor epithelial-mesenchymal transition, immune rejection, metabolic reprogramming, and chemotherapeutic drug resistance. Some DDR1 inhibitors have shown anticancer efficacy in clinical studies. This article reviews the roles of DDR1 in tumor progression and DDR1 inhibitors in tumor therapy to provide new ideas for the targeted therapy of malignant tumors.

Key words: discoidin domain receptor 1, oral squamous cell carcinoma, malignant tumor, inhibitor, targeted therapy

CLC Number: 

  • Q 257

TrendMD: 

Fig 1

The structure and subtype of DDR1"

1 Dang N, Hu J, Liu X, et al. CD167 Acts as a novel costimulatory receptor in T-cell activation[J]. J Immunother, 2009, 32(8): 773-784.
2 Iwai LK, Luczynski MT, Huang PH. Discoidin domain receptors: a proteomic portrait[J]. Cell Mol Life Sci, 2014, 71(17): 3269-3279.
3 Orgel Joseph PRO, Madhurapantula RS. A structu-ral prospective for collagen receptors such as DDR and their binding of the collagen fibril[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(11): 118478.
4 Ongusaha PP, Kim JI, Fang L, et al. p53 induction and activation of DDR1 kinase counteract p53-me-diated apoptosis and influence p53 regulation through a positive feedback loop[J]. EMBO J, 2003, 22(6): 1289-1301.
5 Chang J, Chaudhuri O. Beyond proteases: basement membrane mechanics and cancer invasion[J]. J Cell Biol, 2019, 218(8): 2456-2469.
6 Valencia K, Ormazábal C, Zandueta C, et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis[J]. Clin Cancer Res, 2012, 18(4): 969-980.
7 Hidalgo-Carcedo C, Hooper S, Chaudhry SI, et al. Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6[J]. Nat Cell Biol, 2011, 13(1): 49-58.
8 Toy KA, Valiathan RR, Núñez F, et al. Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer[J]. Breast Cancer Res Treat, 2015, 150(1): 9-18.
9 Xu M, Cui C. Discoidin domain receptor tyrosine kinase 1 (DDR1): a novel predictor for recurrence of hepatocellular carcinoma after curative resection[J]. Med Sci Monit, 2021, 27: e933109.
10 Wu L, Zhao X, Ma H, et al. Discoidin domain receptor 1, a potential biomarker and therapeutic target in hepatocellular carcinoma[J]. Int J Gen Med, 2022, 15: 2037-2044.
11 Bonfil RD, Chen W, Vranic S, et al. Expression and subcellular localization of Discoidin Domain Receptor 1 (DDR1) define prostate cancer aggressiveness[J]. Cancer Cell Int, 2021, 21(1): 507.
12 Sugimoto K, Ito T, Woo J, et al. Prognostic impact of phosphorylated discoidin domain receptor-1 in esophageal cancer[J]. J Surg Res, 2019, 235: 479-486.
13 Chou ST, Peng HY, Mo KC, et al. MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1[J]. J Exp Clin Cancer Res, 2019, 38(1): 281.
14 Chen YL, Tsai WH, Ko YC, et al. Discoidin domain receptor-1 (DDR1) is involved in angiolymphatic invasion in oral cancer[J]. Cancers (Basel), 2020, 12(4): E841.
15 Zhu X, Yao M, Zhang B, et al. Biological information and functional analysis reveal the role of discoidin domain receptor 1 in oral squamous cell carcinoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2021, 131(2): 221-230.
16 Lai SL, Tan ML, Hollows RJ, et al. Collagen indu-ces a more proliferative, migratory and chemoresistant phenotype in head and neck cancer via DDR1[J]. Cancers (Basel), 2019, 11(11): E1766.
17 Takai K, Drain AP, Lawson DA, et al. Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers[J]. Genes Dev, 2018, 32(3/4): 244-257.
18 Krazinski BE, Kiewisz J, Sliwinska-Jewsiewicka A, et al. Altered expression of DDR1 in clear cell renal cell carcinoma correlates with miR-199a/b-5p and patients’ outcome[J]. Cancer Genomics Proteomics, 2019, 16(3): 179-193.
19 Wasinski B, Sohail A, Bonfil RD, et al. Discoidin domain receptors, DDR1b and DDR2, promote tumour growth within collagen but DDR1b suppres-ses experimental lung metastasis in HT1080 xenografts[J]. Sci Rep, 2020, 10(1): 2309.
20 Zhao Z, Zhao S, Luo L, et al. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition[J]. Br J Cancer, 2021, 124(5): 982-994.
21 Xiao Q, Jiang Y, Liu Q, et al. Minor Type Ⅳ collagen α5 chain promotes cancer progression through discoidin domain receptor-1[J]. PLoS Genet, 2015, 11(5): e1005249.
22 Chappell WH, Candido S, Abrams SL, et al. In-fluences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines[J]. Aging (Albany NY), 2020, 12(11): 10194-10210.
23 Deng J, Kang Y, Cheng CC, et al. DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis[J]. JCI Insight, 2021, 6(17): 146133.
24 Dai W, Liu S, Wang S, et al. Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma[J]. Signal Transduct Target Ther, 2021, 6(1): 176.
25 Ziegler AN, Chidambaram S, Forbes BE, et al. Insulin-like growth factor-Ⅱ (IGF-Ⅱ) and IGF-Ⅱ analogs with enhanced insulin receptor-a binding affinity promote neural stem cell expansion[J]. J Biol Chem, 2014, 289(8): 4626-4633.
26 Vella V, Malaguarnera R. The emerging role of insulin receptor isoforms in thyroid cancer: clinical implications and new perspectives[J]. Int J Mol Sci, 2018, 19(12): E3814.
27 Vella V, Nicolosi ML, Cantafio P, et al. DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop[J]. Endocr Relat Cancer, 2019, 26(1): 197-214.
28 Di Martino JS, Nobre AR, Mondal C, et al. A tumor-derived type Ⅲ collagen-rich ECM niche regulates tumor cell dormancy[J]. Nat Cancer, 2022, 3(1): 90-107.
29 Wang CZ, Su HW, Hsu YC, et al. A discoidin domain receptor 1/SHP-2 signaling complex inhibits alpha2beta1-integrin-mediated signal transducers and activators of transcription 1/3 activation and cell migration[J]. Mol Biol Cell, 2006, 17(6): 2839-2852.
30 Azizi R, Salemi Z, Fallahian F, et al. Inhibition of didscoidin domain receptor 1 reduces epithelial-me-senchymal transition and induce cell-cycle arrest and apoptosis in prostate cancer cell lines[J]. J Cell Physiol, 2019, 234(11): 19539-19552.
31 Azizi R, Fallahian F, Aghaei M, et al. Down-regulation of DDR1 induces apoptosis and inhibits EMT through phosphorylation of Pyk2/MKK7 in DU-145 and lncap-FGC prostate cancer cell lines[J]. Anticancer Agents Med Chem, 2020, 20(8): 1009-1016.
32 Chung VY, Tan TZ, Huang RL, et al. Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer[J]. Gene, 2017, 635: 9-15.
33 Walsh LA, Nawshad A, Medici D. Discoidin domain receptor 2 is a critical regulator of epithelial-mesenchymal transition[J]. Matrix Biol, 2011, 30(4): 243-247.
34 Le CC, Bennasroune A, Collin G, et al. LRP-1 promotes colon cancer cell proliferation in 3D collagen matrices by mediating DDR1 endocytosis[J]. Front Cell Dev Biol, 2020, 8: 412.
35 Xie X, Rui W, He W, et al. Discoidin domain receptor 1 activity drives an aggressive phenotype in bladder cancer[J]. Am J Transl Res, 2017, 9(5): 2500-2507.
36 Griffith OL, Spies NC, Anurag M, et al. The prognostic effects of somatic mutations in ER-positive breast cancer[J]. Nat Commun, 2018, 9(1): 3476.
37 Ben Arfi K, Schneider C, Bennasroune A, et al. Discoidin domain receptor 1 expression in colon cancer: roles and prognosis impact[J]. Cancers (Basel), 2022, 14(4): 928.
38 Reger de Moura C, Battistella M, Sohail A, et al. Discoidin domain receptors: a promising target in melanoma[J]. Pigment Cell Melanoma Res, 2019, 32(5): 697-707.
39 Chen Y, Wang X, Deng X, et al. DNA damage repair status predicts opposite clinical prognosis immunotherapy and non-immunotherapy in hepatocellular carcinoma[J]. Front Immunol, 2021, 12: 6769-22.
40 Dimitrios L, Enrico K. Barring the gates to the battleground: DDR1 promotesimmune exclusion in so-lid tumors[J]. Signal Transduct Target Ther, 2022, 7(1): 17.
41 Sun X, Wu B, Chiang HC, et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion[J]. Nature, 2021, 599(7886): 673-678.
42 Zhong X, Zhang W, Sun T. DDR1 promotes breast tumor growth by suppressing antitumor immunity[J]. Oncol Rep, 2019, 42(6): 2844-2854.
43 [No authors listed]. Collagen receptor implicated in immune exclusion[J]. Cancer Discov, 2022, 12(1): 6.
44 Vella V, Malaguarnera R, Nicolosi ML, et al. Insulin/IGF signaling and discoidin domain receptors: an emerging functional connection[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(11): 118522.
45 Vella V, Giuliano M, Nicolosi ML, et al. DDR1 affects metabolic reprogramming in breast cancer cells by cross-talking to the insulin/IGF system[J]. Biomolecules, 2021, 11(7): 926.
46 Lin Y, Jin H, Wu X, et al. The cross-talk between DDR1 and STAT3 promotes the development of hepatocellular carcinoma[J]. Aging (Albany NY), 2020, 12(14): 14391-14405.
47 Denny WA, Flanagan JU. Inhibitors of discoidin domain receptor (DDR) kinases for cancer and inflammation[J]. Biomolecules, 2021, 11(11): 1671.
48 Tao Y, Wang R, Lai Q, et al. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma[J]. Mol Oncol, 2019, 13(9): 1855-1873.
49 Day E, Waters B, Spiegel K, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib[J]. Eur J Pharmacol, 2008, 599(1/2/3): 44-53.
50 Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors[J]. Nat Biotechnol, 2019, 37(9): 1038-1040.
51 Shariati M, Evans KW, Zheng X, et al. Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations[J]. Oncogene, 2021, 40(26): 4425-4439.
52 Bhanumathy KK, Balagopal A, Vizeacoumar FS, et al. Protein tyrosine kinases: their roles and their targeting in leukemia[J]. Cancers (Basel), 2021, 13(2): E184.
53 Berestjuk I, Lecacheur M, Carminati A, et al. Targe-ting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma[J]. EMBO Mol Med, 2022, 14(2): e11814.
54 Vehlow A, Cordes N. DDR1 (discoidin domain receptor tyrosine kinase 1) drives glioblastoma therapy resistance by modulating autophagy[J]. Autophagy, 2019, 15(8): 1487-1488.
55 Vehlow A, Klapproth E, Jin S, et al. Interaction of discoidin domain receptor 1 with a 14-3-3-beclin-1-Akt1 complex modulates glioblastoma therapy sensitivity[J]. Cell Rep, 2019, 26(13): 3672-3683.e7.
[1] Zhou Jinkuo,Zhang Jinhong,Shi Xiaojing,Liu Guangshun,Jiang Lei,Liu Qianfeng. Influences of long noncoding RNA small nucleolar RNA host gene 22 on the cell proliferation, invasion and migration of oral squamous carcinoma cells by regulating microRNA-27b-3p [J]. Int J Stomatol, 2024, 51(1): 52-59.
[2] Li Liheng,Wang Rui,Wang Xiaoming,Zhang Zhiyi,Zhang Xuan,An Feng,Wang Qin,Zhang Fan. Effects of circular RNA hsa_circ_0085576 on cell migration and invasion of oral squamous cell carcinoma by regulating the microRNA-498/B-cell-specific Moloney murine leukemia virus integration site 1 axis [J]. Int J Stomatol, 2024, 51(1): 60-67.
[3] Wu Jiamin,Xia Bin,Yang Hefeng,Xu Biao.. Research progress on cancer-associated fibroblasts in the tumor microenvironment of oral squamous cell carcinoma [J]. Int J Stomatol, 2023, 50(6): 711-717.
[4] Liu Jianglong, Tuerdi Maimaitituxun. Progress of contrast-enhanced ultrasound in the diagnosis of cervical lymph node metastasis from oral squamous cell carcinoma [J]. Int J Stomatol, 2023, 50(5): 514-520.
[5] Zhao Lingfan, Zhou Yang, Ye Xinxin, Zhang Qiang.. Poorly differentiated mucoepidermoid carcinoma of the parotid gland after renal transplantation: a case report [J]. Int J Stomatol, 2023, 50(4): 419-422.
[6] Sheng Nanning,Wang Jue,Nan Xinrong. Research progress on mechanism and treatment of sex-determining region Y box 9 in oral squamous cell carcinoma [J]. Int J Stomatol, 2023, 50(3): 314-320.
[7] Li Hongfang,Chen Zhong,Zhang Suxin.. Research progress on immune checkpoint inhibitor combined with radiotherapy in head and neck squamous cell carcinoma [J]. Int J Stomatol, 2022, 49(5): 614-620.
[8] Zhao Zhuoping,Xin Pengfei,Gao Yang,Zhang Caifeng,Zhang Kuanshou,Liu Qingmei. Research progress on the use of photothermal therapy to treat oral squamous cell carcinoma [J]. Int J Stomatol, 2022, 49(4): 462-470.
[9] Chen Siting,Zhong Xiong,Meng Wenxia.. Research progress on Nod-like receptor protein 3 inflammasome in oral mucosal diseases [J]. Int J Stomatol, 2022, 49(4): 471-475.
[10] Jiang Han,Shen Yingqiang,Chen Qianming. Experimental study of muscarinic receptors on the biological behavior of oral squamous cell carcinoma through Yes related protein signal [J]. Int J Stomatol, 2022, 49(2): 138-143.
[11] Jiang Yulei,Xia Bin,Rao Nanquan,Yang Hefeng,Xu Biao. Exosomes mediate the malignant progression of oral squamous cell carcinoma and its application in diagnosis and treatment [J]. Int J Stomatol, 2021, 48(6): 711-717.
[12] Qian Ying,Gong Jiaxing,Yu Mengfei,Liu Yu,Wei Dong,Zhu Ziyu,Lu Kejie,Wang Huiming. Diagnosis and treatment of ameloblastoma from molecular biology perspective [J]. Int J Stomatol, 2021, 48(5): 570-578.
[13] Ma Pingchuan,Li Chunjie,Li Longjiang. Diagnosis and treatment of salivary duct carcinoma [J]. Int J Stomatol, 2021, 48(4): 459-467.
[14] Gan Jianguo,Gao Pan,Wang Xiaoyi. Research progress on the relationship between circulating tumor cells and oral squamous cell carcinoma [J]. Int J Stomatol, 2021, 48(2): 205-212.
[15] Huang Junwen,Qiao Jie,Mei Zi,Chen Zhuo,Li Yang,Qiao Bin. Expression and clinical significance of lipopolysaccharide binding protein in oral squamous cell carcinoma [J]. Int J Stomatol, 2021, 48(1): 50-57.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .